EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Polygenic Risk Scores in Human Disease

Dimitri J Maamari, Roukoz Abou-Karam, Akl C Fahed

Clinical Chemistry · 2025

DOI: 10.1093/clinchem/hvae190 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Chemistry, 2025. Verfasst von Dimitri J Maamari und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Genomic Medicine, Department of Medicine, Massachusetts General Hospital, Boston, MA, United States. Hauptthemen laut MEDLINE: Multifactorial Inheritance, Genetic Predisposition to Disease. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background Polygenic risk scores (PRS) are measures of genetic susceptibility to human health traits. With the advent of large data repositories combining genetic data and phenotypic information, PRS are providing valuable insights into the genetic architecture of complex diseases and are transforming the landscape of precision medicine. Content PRS have emerged as tools with clinical utility in human disease. Herein, details on how to develop PRS are provided, followed by 5 areas in which they can be used to improve human health: (a) augmenting risk prediction, (b) refining diagnosis, (c) guiding treatment choices, (d) making clinical trials more efficient, and (e) improving public health. Finally, some of the ongoing challenges to the clinical implementation of PRS are noted. Summary PRS can offer valuable information for providers and patients, including identifying risk of disease earlier in life and before the onset of clinical risk factors, guiding treatment decisions, improving public health outcomes, and making clinical trials more efficient. The future of genomic-informed risk assessments of disease is through integrated risk models that combine genetic factors including PRS, monogenic, and somatic DNA information with nongenetic risk factors such as clinical risk estimators and multiomic data. However, adopting PRS in a clinical setting at scale faces some challenges, including cross-ancestry performance, standardization and calibration of risk models, downstream clinical decision-making from risk information, and seamless integration into existing health systems.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multifactorial InheritanceGenetic Predisposition to DiseaseHumansRisk AssessmentRisk FactorsPrecision MedicineGenome-Wide Association StudyGenetic Risk Score

Autor:innen und Institutionen

  • Center for Genomic Medicine, Department of Medicine, Massachusetts General Hospital, Boston, MA, United States.
  • Cardiovascular Disease Initiative, The Broad Institute of MIT and Harvard, Cambridge, MA, United States.
  • Department of Medicine, Harvard Medical School, Boston, MA, United States.
  • Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, United States.
  • Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Maamari, D. J., Abou-Karam, R., & Fahed, A. C. (2025). Polygenic Risk Scores in Human Disease. Clinical Chemistry. https://doi.org/10.1093/clinchem/hvae190

Vancouver

Maamari DJ, Abou-Karam R, Fahed AC. Polygenic Risk Scores in Human Disease. Clinical Chemistry. 2025. doi:10.1093/clinchem/hvae190

BibTeX
@article{Maamari2025,
  author = {Maamari, Dimitri J and Abou-Karam, Roukoz and Fahed, Akl C},
  title = {Polygenic Risk Scores in Human Disease},
  journal = {Clinical Chemistry},
  year = {2025},
  doi = {10.1093/clinchem/hvae190}
}
Kostenlos starten →